ANDA 90938, held by Barr Labs. Ethinyl Estradiol; Norethindrone Acetate, Ferrous Fumarate.
As of Nov 16, 2026, ANDA 90938 (Norethindrone Acetate And Ethinyl Estradiol And Ferrous Fumarate, Ferrous Fumarate), held by Barr Labs, was first approved by FDA on Dec 1, 2014, with 4 approved supplements and 0 published complete response letters.
Junel Fe 24 (norethindrone acetate and ethinyl estradiol tablets and ferrous fumarate tablets) is indicated for use by women to prevent pregnancy. The efficacy of Junel Fe 24 in women with a body mass index (BMI) of >35 kg/m 2 has not been evaluated.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 1, 2014 | Original application | Approved | None posted |
| Norethindrone Acetate And Ethinyl Estradiol And Ferrous Fumarate0.02MG;1MG · tablet;oral | Ethinyl Estradiol; Norethindrone Acetate | Rx |
| Ferrous Fumarate75MG · tablet; oral | Ferrous Fumarate | None (tentative approval) |
| Apr 29, 2022 | Supplement 12Labeling · Standard review | Approved | None posted |
| Feb 16, 2022 | Supplement 11Labeling · Standard review | Approved | None posted |
| Feb 16, 2022 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 16, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Dec 1, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters